Casdin Capital 13F holdings, Q4 2015
Holdings as of December 31, 2015 · filings on SEC EDGAR · latest filing →
Casdin Capital disclosed 27 US equity positions worth $107.4m in its Q4 2015 13F filing. The largest position was 2655787D at 10.1% of the reported book, followed by SG7 and LOXO ONCOLOGY INC.
What did Casdin Capital own in Q4 2015? Top 27 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs prior |
|---|---|---|---|---|---|---|---|
| 1 | 2655787D BLUEPRINT MEDICINES CORP | 10.1% | $10.9m | 412,500 | – | ||
| 2 | SG7 SAGE THERAPEUTICS INC | 7.8% | $8.3m | 143,011 | – | ||
| 3 | LOXO ONCOLOGY INC | 6.7% | $7.2m | 251,500 | – | ||
| 4 | CTMX CYTOMX THERAPEUTICS INC | Healthcare | 6.2% | $6.7m | 321,023 | – | |
| 5 | SPARK THERAPEUTICS INC | 6.1% | $6.6m | 145,000 | – | ||
| 6 | BLUEBIRD BIO INC | 6.0% | $6.4m | 100,000 | – | ||
| 7 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 5.8% | $6.3m | 96,500 | – | |
| 8 | MYOKARDIA INC | 5.5% | $5.9m | 403,872 | – | ||
| 9 | GHDX GENOMIC HEALTH INC | 5.4% | $5.8m | 165,000 | – | ||
| 10 | ILMN ILLUMINA INC | Healthcare | 5.4% | $5.8m | 30,000 | – | |
| 11 | ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 5.3% | $5.6m | 60,000 | – | |
| 12 | EPIZYME INC | 5.0% | $5.3m | 332,500 | – | ||
| 13 | VYGR VOYAGER THERAPEUTICS INC | Healthcare | 4.8% | $5.2m | 236,862 | – | |
| 14 | BIIB BIOGEN INC | Healthcare | 2.6% | $2.8m | 9,000 | – | |
| 15 | FOUNDATION MEDICINE INC | 2.3% | $2.4m | 115,000 | – | ||
| 16 | GNMK GENMARK DIAGNOSTICS INC | 2.2% | $2.4m | 310,000 | – | ||
| 17 | BMY BRISTOL MYERS SQUIBB CO | Healthcare | 2.1% | $2.2m | 32,164 | – | |
| 18 | GLOBAL BLOOD THERAPEUTICS IN | 2.0% | $2.1m | 65,000 | – | ||
| 19 | INVITAE CORP | 1.9% | $2.1m | 250,000 | – | ||
| 20 | KITE PHARMA INC | 1.7% | $1.8m | 30,000 | – | ||
| 21 | DXCM DEXCOM INC | Healthcare | 1.3% | $1.4m | 17,000 | – | |
| 22 | OSUR ORASURE TECHNOLOGIES INC | Healthcare | 1.0% | $1.1m | 170,000 | – | |
| 23 | OXFORD IMMUNOTEC GLOBAL PLC | 0.8% | $863.0k | 75,000 | – | ||
| 24 | JUNO THERAPEUTICS INC | 0.7% | $769.0k | 17,500 | – | ||
| 25 | ATRA ATARA BIOTHERAPEUTICS INC | Healthcare | 0.6% | $660.0k | 25,000 | – | |
| 26 | MEDIDATA SOLUTIONS INC | 0.5% | $493.0k | 10,000 | – | ||
| 27 | TROVAGENE INC | 0.4% | $378.0k | 70,000 | – |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.